In situ androgen producing enzymes in human prostate cancer

Endocrine-Related Cancer

Volumn 12, Issue 1, 2005, Pages 101-107

  Nakamura, Yasuhiro ^a   Suzuki, Takashi ^a   Nakabayashi, Masao ^a   Endoh, Mareyuki ^a   Sakamoto, Kazuhiro ^a   Mikami, Yoshiki ^a   Moriya, Takuya ^a   Ito, Akihiro ^a   Takahashi, Shoki ^a   Yamada, Shogo ^a   Arai, Yoichi ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 5; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN METABOLISM; ANDROGEN RELEASE; ANDROGEN SYNTHESIS; ARTICLE; CANCER CELL; CANCER HORMONE THERAPY; CANCER SURGERY; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROSTATE CANCER; PROSTATE SURGERY; PROTEIN EXPRESSION;

17-HYDROXYSTEROID DEHYDROGENASES; AGED; ANDROGENS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 20144389477     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00914     Document Type: Article

References (30)

1. Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB & Rittmaster RS 2004 Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. Journal of Urology 172 915-919.
2. Brown CT & Nuttall MC 2003 Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. International Journal of Clinical Practice 57 705-709.
3. Brufsky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I, Kaufman D & Kantoff P 1997 Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 49 913-920.
4. Delos S, Carsol JL, Fina F, Raynaud JP & Martin PM 1998 5alpha-reductase and 17β-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate. International Journal of Cancer 75 840-846.
5. Dufort I, Rheault P, Huang XF, Soucy P & Luu-The V 1999 Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase. Endocrinology 140 568-574.
6. ehle C, Radvanyi F, Gil Diez de Medina S, Ouafik LH, Gerard H, Chopin D, Raynaud JP & Martin PM 1999 Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. Journal of Steroid Biochemistry and Molecular Biology 68 189-195.
7. Imperato-McGinley J, Gautier T, Zirinsky K, Hom T, Palomo O, Stein E, Vaughan ED, Markisz JA, Ramirez de tArellano E & Kazam E 1992 Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. Journal of Clinical Endocrinology and Metabolism 75 1022-1026.
8. Koh E, Noda T, Kanaya J & Namiki M 2002 Differential expression of 17β-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53 154-159.
9. Labrie F 1991 Endocrine therapy for prostate cancer. Endocrinology and Metabolism Clinics of North America 20 845-872.
10. Li SC, Chen GF, Chan PS, Choi HL, Ho SM & Chan FL 2001 Altered expression of extracellular matrix and proteinases in Noble rat prostate gland after long-term treatment with sex steroids. Prostate 49 58-71.
11. Lopez-Otin C & Diamandis EP 1998 Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocrine Reviews 19 365-396.
12. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET & Namiki M 2004 The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Research 64 765-771.
13. Nam RK, Toi A, Vesprini D, Ho M, Chu W, Harvie S, Sweet J, Trachtenberg J, Jewett MA & Narod SA 2001 V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 57 199-204.
14. Negri-Cesi P, Poletti A, Colciago A, Magni P, Martini P & Motta M 1998 Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate 34 283-291.
15. O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P & Hofner K 2003 Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU International 92 262-266.
16. Pelletier G, Luu-The V, Tetu B & Labrie F 1999 Immunocytochemical localization of type 5 17β-hydroxysteroid dehydrogenase in human reproductive tissues. Journal of Histochemistry and Cytochemistry 47 731-738.
17. Presti JC Jr, Fair WR, Andriole G, Sogani PC, Seidmon EJ, Ferguson D, Ng J & Gormley GJ 1992 Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. Journal of Urology 148 1201-1204.
18. Ross RK & Henderson BE 1994 Do diet and androgens alter prostate cancer risk via a common etiologic pathway? Journal of the National Cancer Institute 86 252-254.
19. Russell DW & Wilson JD 1994 Steroid 5α-reductase: two genes/two enzymes. Annual Reviews of Biochemistry 63 25-61.
20. Silver RI, Wiley EL, Thigpen AE, Guileyardo JM, McConnell JD & Russell DW 1994 Cell type specific expression of steroid 5α-reductase 2. Journal of Urology 152 438-442.
21. Soderstrom T, Wadelius M, Andersson SO, Johansson JE, Johansson S, Granath F & Rane A 2002 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 12 307-312.
22. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J & Koki AT 2000 COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 2637-2645.
23. Steers WD 2001 5alpha-reductase activity in the prostate. Urology 58 17-24.
24. Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T & Sasano H 2001 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. Journal of Clinical Endocrinology and Metabolism 86 2250-2257.
25. Suzuki T, Sasano H, Kimura N, Tamura M, Fukaya T, Yajima A & Nagura H 1994 Immunohistochemical distribution of progesterone, androgen and oestrogen receptors in the human ovary during the menstrual cycle: relationship to expression of steroidogenic enzymes. Human Reproduction 9 1589-1595.
26. Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, Griffin JE, Francke U, Wilson JD & Russell DW 1992 Molecular genetics of steroid 5α-reductase 2 deficiency. Journal of Clinical Investigation 90 799-809.
27. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD & Russell DW 1993 Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. Journal of Clinical Investigation 92 903-910.
28. Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, Thompson IM, Troyer DA, Rittmaster RS & Lazier CB 2003 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. Journal of Urology 170 2019-2025.
29. Torres JM, Ruiz E & Ortega E 2003 Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in rat prostate in different androgen status. Prostate 56 74-79.
30. Veltri RW, Miller MC, Partin AW, Coffey DS & Epstein JI 1996 Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology 48 685-691.